ONC206: Clinical Trials

2 trials of ONC206, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Active not recruiting 1, Recruiting 1

Follow ONC206: new trials by email Literature Review of ONC206 trials Research Report on ONC206

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS) - Diffuse Midline Glioma (DMG), Glioblastoma
Phase 1RecruitingSabine Mueller, MD, PhD2082021-08-232026-06-11
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
ONC206 - Central Nervous System Neoplasms, Glioblastoma
Phase 1Active not recruitingJazz Pharmaceuticals352020-10-262026-11-09

Conditions studied

Central Nervous System Neoplasms (2)  ·  Ependymoma (2)  ·  Glioblastoma (2)  ·  Astrocytoma (1)  ·  Choroid Plexus Neoplasms (1)  ·  Glioma (1)  ·  Gliosarcoma (1)  ·  Medulloblastoma (1)  ·  Meningioma (1)  ·  Neoplasms, Neuroepithelial (1)  ·  Neuroectodermal Tumors (1)  ·  Neuroectodermal Tumors, Primitive (1)  ·  Oligodendroglioma (1)  ·  Pinealoma (1)  ·  Typical Teratoid Rhabdoid Tumor (1)

Sponsors

Jazz Pharmaceuticals (1)  ·  Sabine Mueller, MD, PhD (1)

Countries

United States (2)  ·  Netherlands (1)  ·  Switzerland (1)

Top investigators

Sabine Mueller, MD, PhD (1)

Results publications

PMID 35157764, PMID 35417530, PMID 41256696

NIH funding

R01CA266596 (1)